News | Contrast Media | November 29, 2015

Guerbet Completes Acquisition of Mallinckrodt’s Contrast Media and Delivery Systems Business

Guerbet board of directors approves 100 percent acquisition of Mallinckrodt division for $270 million

November 29, 2015 — Guerbet announced that it has completed its acquisition of the "contrast media and delivery systems" (CMDS) business of Mallinckrodt. The new entity brings together 2,500 employees, with a pro forma turnover of about €800M.

Guerbet’s board of directors approved the acquisition of the CMDS activity of Mallinckrodt on November 18.

The transaction has all necessary regulatory approvals and the customary closing conditions have been met.

Guerbet is acquiring 100 percent of the Mallinckrodt CMDS business for $270M total, paid in cash and financed by a loan syndicated by BNP Paribas. The acquisition relates to companies with their production sites, intellectual property rights and distribution subsidiaries in the various geographical areas. 

The complementary strengths of Guerbet and CMDS promise to bring rapid benefits, according to both companies: 

The strengths of Guerbet and CMDS will complement each other in several areas, according to the companies:

  • In contrast agents, where CMDS features Optiray and Optiject (Europe) / Ultraject (USA) in X-rays, and Guerbet offers Dotarem in magnetic resonance imaging (MRI);
     
  • In Imaging Solutions and Services, with CMDS’ syringe-based delivery systems and Guerbet’s  hydraulic injection technique for soft bags; and
     
  • From a geographical perspective, a similar synergy exists with a strong position of CMDS in the United States and Guerbet in Europe. In addition, Guerbet will strengthen its presence on markets with high growth potential, particularly in China, Russia, and Turkey.

In the medium-term, the group will achieve significant economies of scale, particularly by using the existing infrastructure and commercial networks to sell new products:

  • By pooling R&D and marketing resources;
  • By optimizing the purchasing, logistics and general spending policies of the two entities.

For more information: www.guerbet.com

Related Content

Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...
Bracco Receives FDA Approval for Varibar Thin Liquid for Oral Suspension
Technology | Contrast Media | August 05, 2019
Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
GU12171120

GU12171120

Sponsored Content | Case Study | Contrast Media Injectors | April 02, 2019
The continuing search for advantages to improve workflow has radiology departments constantly searching for new solut
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...